Literature DB >> 27043339

Cutaneous Osteoblastic Osteosarcoma: Report of 2 New Cases Integrated With SATB2 Immunohistochemistry and Review of the Literature.

Giovanni Falconieri1, Palmina Cataldi, Rajko Kavalar, Vesna Štitič, Boštjan Luzar.   

Abstract

We report 2 cases of primary dermal osteosarcoma. The patients were an 88-year-old man and a 72-year-old man complaining of masses occurring in the ear pavilion and the palm, deemed suspicious for basal cell carcinoma and metastatic colonic carcinoma, and were treated by resection. Microscopically, both featured a dermal lesion mostly composed of atypical spindle cells within a fibrous to hyaline matrix often showing mineralization. Osteoid material was rimmed by atypical tumor cells and was also associated with osteoclast-like giant cells. Tumor cells were positive for SATB2 and negative for markers of epithelial (low-molecular and high-molecular weight cytokeratins, epithelial membrane antigen, p63), melanocytic (S100 protein, HMB45, Melan A), and skeletal/smooth muscle differentiation (desmin, myogenin). No further therapy has been administered. Follow-up at 6 (case 1) and 8 months (case 2) was uneventful. A brief differential diagnosis discussing cutaneous tumors capable of showing osseous differentiation is summarized, along with a review of the pertinent literature. The specificity and sensitivity of SATB2 is also shortly addressed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27043339     DOI: 10.1097/DAD.0000000000000555

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  2 in total

1.  Primary cutaneous osteosarcoma of the scalp.

Authors:  Yusra Al-Janabi; Khalid Al-Janabi; Kallirroi Tzafetta; Mahir Petkar
Journal:  BMJ Case Rep       Date:  2018-05-18

2.  TNF-α inhibits SATB2 expression and osteoblast differentiation through NF-κB and MAPK pathways.

Authors:  Chijian Zuo; Xiaoying Zhao; Yu Shi; Wen Wu; Ning Zhang; Jiake Xu; Chuandong Wang; Guoli Hu; Xiaoling Zhang
Journal:  Oncotarget       Date:  2017-12-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.